Condition
Severe Hypertriglyceridemia (sHTG)
Total Trials
4
Recruiting
1
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 15/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
4Total
Early P 1 (1)
P 1 (1)
P 2 (1)
P 3 (1)
Trial Status
Not Yet Recruiting2
Completed1
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07491172Phase 1Recruiting
A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
NCT07693777Phase 3Not Yet RecruitingPrimary
A Phase III Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia
NCT07657780Early Phase 1Not Yet RecruitingPrimary
CS-121 APOC3 Base Editing in Severe Hypertriglyceridemia
NCT03452228Phase 2CompletedPrimary
Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis
Showing all 4 trials